Mareike Roscher

Heidelberg, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study.

Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study.

Journal: BMC cancer

Published: May 17, 2026

A unified single-cell atlas of HNSCC: Toward characterizing HPV- and sex-associated TME variability.

A unified single-cell atlas of HNSCC: Toward characterizing HPV- and sex-associated TME variability.

Journal: iScience

Published: January 23, 2026

Differential Radiobiological Effects of Αlpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival.

Differential Radiobiological Effects of Αlpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival.

Journal: International journal of radiation oncology, biology, physics

Published: January 15, 2026

PSMA-targeting hybrid molecule PSMA-914 for preoperative imaging and intraoperative fluorescence-guidance: A first-in-human experience.

PSMA-targeting hybrid molecule PSMA-914 for preoperative imaging and intraoperative fluorescence-guidance: A first-in-human experience.

Journal: Theranostics

Published: December 12, 2025

EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer.

EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer.

Journal: Molecular therapy. Oncology

Published: November 18, 2025

Genomic analysis in chemotherapy-naïve prostate cancer prior to PSMA-targeted treatment.

Genomic analysis in chemotherapy-naïve prostate cancer prior to PSMA-targeted treatment.

Journal: Frontiers in oncology

Published: November 06, 2025

Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancer.

Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancer.

Journal: EJNMMI research

Published: October 02, 2025

Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy.

Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: June 12, 2024

Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617 Uptake?

Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617 Uptake?

Journal: Pharmaceuticals (Basel, Switzerland)

Published: March 07, 2024

Synthesis of tritium-labeled Lu-PSMA-617: Alternative tool for biological evaluation of radiometal-based pharmaceuticals.

Synthesis of tritium-labeled Lu-PSMA-617: Alternative tool for biological evaluation of radiometal-based pharmaceuticals.

Journal: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine

Published: January 31, 2023

Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors.

Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors.

Journal: Molecular pharmaceutics

Published: April 25, 2022

A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer.

A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: December 22, 2021

Showing 1-12 of 29

Last Updated: 09/26/2026